menu
    • menu

    Company profile for Biovaxys

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BioVaxys is a clinical-stage biopharma developing antiviral & anticancer vaccine platforms. The Company is evaluating a potential SARS-CoV-2 vaccine based on its haptenized viral protein technology, and advancing a compassionate use trial in the EU to evaluate its haptenized cell vaccine for late-stage ovarian cancer. In addition to our haptenized cell vaccines for ovarian cancer and other tumor types, we are exploring ways we...
    BioVaxys is a clinical-stage biopharma developing antiviral & anticancer vaccine platforms. The Company is evaluating a potential SARS-CoV-2 vaccine based on its haptenized viral protein technology, and advancing a compassionate use trial in the EU to evaluate its haptenized cell vaccine for late-stage ovarian cancer. In addition to our haptenized cell vaccines for ovarian cancer and other tumor types, we are exploring ways we can leverage our technology platform in the field of Adoptive Immunotherapy, which is also of significant interest in the immune-oncology market.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BiovaxysCanada Flag
    Country
    Country
    Canada
    Address
    Address
    Etobicoke, Ontario
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://biovaxys.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biovaxys-llc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biovaxys Closes (LIFE) Private Placement Financing
    Biovaxys Closes (LIFE) Private Placement Financing

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251119390038/en/BioVaxys-Technology-Corp.-Closes-Listed-Issuer-Financing-Exemption-LIFE-Private-Placement

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    Biovaxys Announces Extension Of Life Offering Closing Date
    Biovaxys Announces Extension Of Life Offering Closing Date

    11 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/11/3185747/0/en/BioVaxys-Announces-Extension-of-Life-Offering-Closing-Date.html

    GLOBENEWSWIRE
    11 Nov 2025
    Share Share
    Biovaxys Announces Conversion of Debentures
    Biovaxys Announces Conversion of Debentures

    28 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biovaxys-announces-conversion-of-debentures-302596570.html

    PR NEWSWIRE
    28 Oct 2025
    Share Share
    BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
    BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES

    22 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biovaxys-announces-conversion-of-debentures-302591260.html

    PR NEWSWIRE
    22 Oct 2025
    Share Share
    BIOVAXYS Converts DEBENTURES Awards STOCK OPTIONS
    BIOVAXYS Converts DEBENTURES Awards STOCK OPTIONS

    21 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biovaxys-announces-conversion-of-debentures-and-grant-of-stock-options-302589535.html

    PR NEWSWIRE
    21 Oct 2025
    Share Share
    BioVaxys Licensee Reports Positive SpayVac Single-Dose Efficacy
    BioVaxys Licensee Reports Positive SpayVac Single-Dose Efficacy

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biovaxys-licensee-spayvac-for-wildlife-inc-reports-further-positive-single-dose-efficacy-data-for-its-immunocontraceptive-vaccine-and-initiation-of-regulatory-submission-process-302583129.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search